PetLife Pharmaceuticals is launching a new line of veterinary products called Escozine for Pets. Escozine for Pets is based on a patented formula called Escozine that contains extracts from blue scorpion venom and has been used to treat cancer in humans. PetLife will launch nutraceutical and prescription strength versions of Escozine for Pets to treat and prevent cancer in dogs and cats. Over 12 million pets are diagnosed with cancer each year, but 90% go untreated due to the side effects and costs of chemotherapy. PetLife believes Escozine for Pets can provide an affordable, less toxic alternative to chemotherapy to improve outcomes for pets with cancer.

1. Corporate Presentation
October 2014
PetLife Pharmaceuticals, Inc.
A NEW GENERATION IN VETERINARY MEDICINE
OTCQB: PTLF

2. 2OTCQB: PTLF
This document is being provided by PetLife solely for the information of those persons to whom it is
transmitted. No person in any jurisdiction may treat this document as constituting either an offer to
sell or solicitation of an offer to buy any securities in the Company. A prospective subscriber must rely
solely on the terms of and disclosure of information including important information regarding risks
and conflicts of interest contained in the Company's final offering memorandum and related
documents, the only basis on which subscriptions may be made.
Safe Harbor Statement
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages
those interested in our Company to rely only on information included in our filings with the United
States Securities and Exchange Commission which can be found at www.sec.gov. Statements released
by PetLife that are not purely historical are forward-looking within the meaning of the "Safe Harbor"
provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the
company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that
forward-looking statements involve risk and uncertainties that may affect the company's business
prospects and performance. The company's actual results could differ materially from those in such
forward-looking statements. Risk factors include but are not limited to general economic, competitive,
governmental, and technological factors as discussed in the company's filings with the SEC on Forms
10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-
looking statements contained in this release.
Safe Harbor
© PetLife Pharmaceuticals, Inc. – All rights reserved

3. 3OTCQB: PTLF
Snapshot (OTCQB: PTLF)
Trading Statistics
Price $0.85
Volume (3 month) 2,885
52 Week High/Low $1.57/$0.16
Total Shares Outstanding 58.0M
Float 11.0M
% Insiders 52%
Market Cap $50M
Other
Headquarters Beverly Hills, CA
Public Since August 12, 2014
Website www.PetLifepharma.com

4. 4OTCQB: PTLF1American Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.
About PetLife
• PetLife Pharmaceuticals (PetLife) has developed
and is launching a new generation of high-potency
veterinary oncology medications & nutraceuticals
• Escozine for Pets™ is based on the same patented
formula of “Escozine” used for the treatment of
cancer in humans but is amplified through
polarization technology
• Escozine for humans uses blue scorpion venom &
is currently sold as either a nutraceutical or
prescription drug in 40 countries, including the U.S.
• Over 12 million dogs and cats are diagnosed with
cancer annually. Our products will be utilized as
both a preventative & treatment of cancer.

5. 5OTCQB: PTLF
$22.6
$15.3
$2.2
$4.7
Estimated 2014 Pet Sales within the U.S.
($ in billions)
Food
Supplies/OTC Medicine
Vet Care
Live animal purchases
Pet Services: grooming
& boarding
1American Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.
Large, Growing Addressable Market
• Consumer spending on pets is ~$58
billion in 2014 and expected to grow
4%-6% annually
• In 2013, $13+ billion was spent on
over-the-counter medications for
pets
• Each year, 6.0M dogs and 6.5M cats are
diagnosed with cancer in the U.S.
• It’s estimated that ~10% of those
diagnosed receive treatment
• 90% of dogs & cats go untreated due to
prohibitive costs and side effect of
treatments
• Dogs and cats are ~35 times more
likely to suffer from cancer than
humans1

6. 6OTCQB: PTLF1American Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.
Why PetLife?
• Tragically, 12.5 million pet owners who leave
the vet’s office with a pet cancer diagnosis
annually must decide:
• Chemotherapy and/or surgery?
• Escozine?
• Or do nothing?
• Our patented polarization technology allows us
to amplify the potency of blue scorpion venom
by +10x, allowing Escozine to:
• Enhance binding preference to cancerous cells
• Decrease the toxic side effects
• Decrease cost of production
• PetLife’s sister company, Medolife, has provided
the worldwide rights to formulate, package and
market a new product line, “Escozine for Pets™

7. 7OTCQB: PTLF
Medolife
Research and Development
Medolife is dedicated to R&D of alternative natural products to effectively improve health at
a cellular level. Escozine™ containing small molecular peptides (chlorotoxin “CLTX”)
extracted from blue scorpion serum is an oncology therapy. Pre-clinical research
demonstrates Escozine™ ability to kill cancer cells in animals (UCSD Moores Cancer Center,
2012)
Markets Addressed
Since 2007, Escozine™ for cancer prevention & treatment has been sold in 40 countries.
High Quality Production
Advanced production protocols to ensure the highest potency of Escozine™. Medolife has a
first-of-its-kind scorpion reservation on the Caribbean island of Hispaniola, which is ideal
habitat to support a healthy population of blue scorpions.
Pet Centric Opportunity
Humans, dogs and cats share similar histology. PetLife signed a worldwide license to Arthur
Mikaelian’s IP and production patent # US 8097284 B2 and commenced operations.
Sister Company Medolife invested $10 M
over 10 years in Escozine for Humans

8. 8OTCQB: PTLF
Escozine for Pets is produced in US FDA-approved facility in Commerce,
California.
Clear liquid nutraceutical -- 2 versions for launch: Cancer Treatment &
Prevention. Edibles to follow.
Escozine contains “CLTX” peptide extracts from Blue Scorpion venom, harvested
from scorpions at farms in the Caribbean where PetLife has significant
production capacity.
Patented polarization technology involves specific frequencies and harmonics,
to achieve a resonance between the electromagnetic frequencies and the
molecular frequency of the small molecular peptide “CLTX”.
Polarized Dilute Blue Scorpion Venom solution leads to more apoptosis vs. non.
See U.S. Patent 8,097,284 B2, as it pertains to Polarized Scorpion Venom
solution, and the method for producing it.
PetLife – What is Escozine for Pets?

9. 9OTCQB: PTLF
Historically, the FDA process for similar types of pet products is straightforward and
typically approved in 9 to 15 months.
Launch 1st product -- a
nutraceutical version of
Escozine for PetsTM – in
Fall 2014.
Introduce a line of
Escozine for PetsTM
preventative dog and
cat treats, and an
arthritis product,
scheduled for
introduction in Q1-15.
Concurrently, apply to
US FDA in Q4-14 (ANDA)
for approval of Rx
strength versions for use
by veterinarians:
•IV administered
•Injectable version for
direct into tumors.
Product Roadmap

10. 10OTCQB: PTLF
_________________________________________________________________________
VENOMICS: “In the future, it can be envisaged that almost the full extent of the 40,000,000
biologically active molecules found in animal venoms will become available as a resource for drug
discovery.”
“This will offer a plethora of new opportunities in drug discovery and will permit the consortium to
undertake in-house drug development and generate licensing opportunities for pharmaceutical
companies in dire need of novel drug sources.”
The VENOMICS consortium is composed of 8 partners representing
5 countries (France, Spain, Portugal, Belgium and Denmark), and is a
mix of academic laboratories , SMEs and biotech firms devoted to
novel drug discovery that aims at implementing a faster and more
efficient strategy for the exploitation of venoms as a drug discovery
resource.
It has been assembled by VenomeTech, project leader, to select the
best European experts in the fields of transcriptomics, proteomics,
peptide production and drug discovery.
Venom-Based Medication
Gaining Traction & Government Support
A Science Gaining Traction and Gov’t Support
www.venomics-project.eu

11. 11OTCQB: PTLF
Venomics in the News
Bee, scorpion and snake venom may hold
cancer cure
By Jen Christensen, CNN
updated 9:26 AM EDT, Tue August 12, 2014
(CNN) -- It's ancient medicine with a sci-fi-sounding twist.
A scientist at the University of Illinois, Dipanjan Pan, and his team
say they may have found a way to stop cancer cell growth,
according to a paper presented at the American Chemical Society
conference this week.
The work is in very early stages, but has shown success in stopping
breast cancer and melanoma cell growth in lab tests. Pan’s
technique uses nanotechnology to deliver a synthesized element
similar to the venom found in bees, snakes & scorpions.
Alternative doctors in Cuba have used scorpion venom to fight brain tumors.
Read the Full Article on CNN.com

12. 12OTCQB: PTLF
Research Studies on Blue Scorpion Serum
(an Active Ingredient in Escozine For Pets™)
• UCSD Moores Cancer Center: Pre-clinical tests in 2012 demonstrated Escozine’s ability to target
and kill malignant cells in animals as well as its synergy when used with traditional
chemotherapy.
• Cedars Sinai Medical Center & City of Hope, CA: Scientists demonstrated “Synthetic Version of
Scorpion Venom Delivers Radioactive Iodine to Malignant Brain Tumors.”
• Suez Canal University, Egypt: Cytotoxic and apoptotic effect of scorpion venom demonstrated in
this study by Dr. Omran.
• University of Alabama at Birmingham: Discovered chemical compounds in the scorpion's
venom could be used to kill cancerous cells in brain without harming the healthy cells nearby.
• Transmolecular received FDA approval that synthetic Chlorotoxin (CLTX) crosses blood-brain and
tissue barriers & binds preferentially to glioma cells without affecting surrounding healthy
tissue. Escozine’s natural CLTX - superior.
• Seattle Children's Hospital: In conjunction with Prof. Fred Hutchinson at Cancer Research
Center - Seattle has re-engineered the scorpion venom protein which binds to cancer cells, and
is then joined with a fluorescent molecule "flashlight" to create a “tumor paint” to identify
cancer cells.

13. 13OTCQB: PTLF
Research Studies on Blue Scorpion Serum - II
(an Active Ingredient in Escozine For Pets™)
• Labiofam laboratory, Cuba: Study demonstrated that the Blue Scorpion venom causes
cell death of malignant cells and is anti inflammatory and analgesic.
• Labiofam laboratory, Cuba: Dr. Mikaelian participated in an open label human study
with 8,302 patients commissioned by the Cuban pharmacological company, Labiofam. It
demonstrated Blue Scorpion venom to be therapeutically effective ranging from
improvement in quality of life to remission of malignant cancer cells across a broad
spectrum of cancer types.
• University of Washington: Scorpion venom with nanoparticles slows spread of brain
cancer.
• University of Massachusetts, Amherst: A study released suggests that anti-cancer
chemotherapies which use (polarized) nanoparticles to deliver drugs deep inside tumor
tissue will be more effective if the particles are positively electrically charged because
they are taken up to a greater extent by proliferating cells.

14. 14OTCQB: PTLF
Dr. Raul Jimenez - Biscayne Veterinary Center
• Doctor of Veterinary Medicine (DVM) for 30 years. Education from
Cornell, Auburn and University of Florida.
• Principle of Biscayne Veterinary Center – Miami-based 24-hour
veterinary hospital.
“Approximately eight months ago, my team started a medical trial treatment program for a
group of 14 dogs and 3 cats diagnosed with cancer; adding the PetLife product after either
tumoral surgical excision and/or oncology therapies. The outcome has been incredible. We
have witnessed absolutely no negative side effects using this product with our patients. The
results to date have ranged from: a.) completely slowing or halting the cancer’s progression
b.) tumor reduction c.) systemic cancers in remission. The positive side effects have
included: a.) all of the dogs and cats treated have regained a dramatically improved quality
of life b.) an increase in their appetite c.) a dramatic improvement in both their energy level
and mood.
“I am pleased to wholeheartedly endorse PetLife as a product that should be used alone,
and/or in conjunction with other clinical therapies for pets stricken with cancer. We plan to
continue documenting our clinical data and to submit the results to our veterinary medical
community.”
Veterinary Testimonial
Dr. Jimenez with dogs

15. 15OTCQB: PTLF
Geoff and Buddy
• Golden Retriever
• Small tumor called anal sac adenocarcinoma
• Aggressive cancer, which is usually followed by chemo and radiation
• Not a treatable cancer and surgery is only used as a band aid.
• Like a gift from God, a friend told me about PetLife.
• It's so easy!
• Orally 3 times a day and because of his type of cancer, I also administer the solution as an
enema a few times a week.
• 6 months later, he is still acting happy and healthy!!
• He's still acting like a puppy, and giving me lots of licks and love!!!!
Thanks PetLife!!!
Geoff
Gita and Micky
• Micky an American Eskimo, is 14
• Recently diagnosed with sarcoma
• Huge growth on his shoulder, which causes so much hurt and pain
• In pain and was fatigued all day long and couldn't move much
• The vet advised me not to operate
• There is no hope for my Micky to live that much longer
• Within 10 days [of starting Escozine treatments] Mickey started having so much energy
• The sparkle is back in his eyes, he has so much appetite now and looks like a happy Mickey
Our family is so thankful to PetLife,
Gita
Customer Testimonials

16. 16OTCQB: PTLF
Escozine For Pets is a category creating nutraceutical
with no direct competition. Surgery carries its own risks.
Chemotherapy treatment for dogs and cats with cancer is
expensive and toxic -- with the same side effects: nausea,
diarrhea, lost appetite, cachexia (‘wasting” loss of muscle and fat
tissues) headache, hair loss, liver and kidney toxicity and
susceptibility to opportune infections and more.
Vet chemo treatments fall into two categories:
• Off-label use of human oncology products
• Specifically registered drugs for veterinary oncology:
o Palladia – Pfizer/Zoetis. First pet specific chemo drug
o Paccal/Kina Vet-CA1 - Oasmia Pharmaceutical AB,
Uppsala Sweden -- “Conditionally approved”
The full effectiveness of Paccal Vet®-CA1 has yet to be
demonstrated to the FDA. It has been prevented from entering
the market in certain countries because of high toxicity and
severe side effects.
 The cost to simply receive diagnosis is $200-$500
 Chemotherapy , depending on type and stage of cancer,
ranges $2,000 to $10,000
 Requires a tremendous time commitment from owner
 Takes a major toll on the quality of the pet’s life
 Standard of care has a success rate ~ 40%
Comparison of Escozine for Pets™
with Chemo Products
Product Name Paccal/Kin
a Vet-
CA1™
Palladia™ Escozine for
Pets™
Years In the Market 2 5 7
Toxicity Level
0-10*
--10 --10 0
Efficacy Level
0-10*
7 4 8
Supportive Medication
required to control side
effects
0-10*
--10 --10 0
Cost of the Product
0-10*
--4
$507
--7
$975
--3
$358
Patent*
0=No 10= Yes
10 10 10
FDA
Registration*
0=No 10= Yes
10 10 0
Total Score 5 1 28
Scale: --10 to +10
Current Pet Chemo Choices

17. 17OTCQB: PTLF
Brand Strategy & Roadmap
Launch Escozine for Pets™
Aggressive multi-channel marketing strategy
FDA clinical trials for Rx products
Build intellectual property portfolio & leverage portfolio to introduce new products
Evaluate for use in U.S. livestock market, which suffers from high rates of cancer
Expand internationally (i.e. China, UK, Canada & Brazil)

18. 18OTCQB: PTLF
PetLife Marketing Plan – Multi-Channel
Online
• Implement an aggressive direct-to-consumer online marketing campaign to drive US and select
International sales.
• Utilize integrated SEO, Facebook, & Banner Ad Campaign to target pet owners and thought leaders
Retail
• Market to distributors and brick & mortar outlets such as PetSmart and Petco
Veterinarians
• Utilize specialized, vertical marketing firm to both educate and sell to the vet market
Multi-level Marketing
• Partnered with a proven multi-level marketing (MLM) platform to drive affiliate sales
• MLM partner will utilize an initial sales and marketing force of 100 people
Direct Response: Infomercials
• Retail sales driven by infomercials range from 2 to 15 times the infomercial sales
• Partner with well-known celebrity, well-respected veterinarian, to film differentiated 2 to 30 minute
infomercials on Escozine for Pets™
Promotion
• Direct to vet, direct to consumer, direct to wholesaler
• Trade shows, direct vet outreach and online webinars
Media
• Engage industry relevant PR firm to generate media coverage for products in general news, family,
pet and veterinarian publications, e-zines, videos and the blogosphere to communicate Escozine for
Pets™ features and benefits

19. 19OTCQB: PTLF
Revenue opportunity = % of market penetration
• Revenue sources: Preventative, cancer & post-cancer therapy products and, if successful, FDA
approved Rx products.
• Assumes multiple pets and growing % of recurring (auto-ship) purchases
 Gross Margins targeted above 70% with ASP to customer of $356 per month
 FDA clinical trial expenses forecasted at $8 - $10 million total for both Rx products
~12.5 million dogs & cats diagnosed with cancer annually: owners must make a decision
 0.25% market penetration = $133 million revenue
 0.5% market penetration = $266 million revenue
PetLife Financial Model
Palladia is 1st Pet-Specific FDA approved Oncology Product
 Palladia (chemo) approved 2009 - dogs only
 Spent ~$15 million clearing FDA. (Today, est. cost is $8M - $10M)
 Year One: spent ~$1M on marketing  generated ~$150M in sales

20. 20OTCQB: PTLF
PetLife Management
Strategic partners
Samson Pharmaceuticals, Commerce, CA
– US FDA approved facility, manufactures PetLife products.
Aguas Vivas Laboratory, Santo Domingo, DR
– Venom extraction and compound preparation
Arthur G. Mikaelian, Ph.D., Founder, CEO and President
• Invented patented Polarization technology
• Researching stress hormones (cortisol, epinephrine), master gene (ATF3) and their indirect influences on cancer
cell activity and tumor progression.
• Ph.D. Biological Psychology - Vernadsky University of Biosphere Knowledge, Moscow
Bruce Niswander, Chief Financial Officer
• 30 years commercializing new, entrepreneurial ventures
• MBA and JD from Ohio State University
• Certified Financial Analyst (CFA)
Vivek Ramana, Chief Medical Officer
• Prior, Ambit Biosciences Senior Safety Medical Officer/Senior Medical Director
Previously, AdPharma CMO & President
• Former Medical Director, R&D for Pharmaceutical Clinical Research, JVs BMS, Pfizer, Schering Plough, Astra
Zeneca
• Post-Doctoral Studies in Clinical Pharma, Drug R&D and Regulation from TUFTS University in Boston

21. 21OTCQB: PTLF
PetLife to Launch
Escozine for PetsTM
nutraceutical in Fall 2014
US: Over 12 million cats
and dogs are diagnosed
with cancer each year
US $13 billion TAM for
OTC vet meds. Total US
2014 pet spend=$58B
Multi-channel market
strategy: Direct, PR, retail,
vet clinics, infomercial,
affiliate sales
Highly Experienced
Industry Management
and R&D Team (Medolife)
Breakthrough science
with new therapy.
Currently vets use toxic
human chemo drugs,
scaled by pets’ weight
Highly Scalable business
with targeted Gross
margins of 70%+
1American Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.
Investment Summary

22. 22OTCQB: PTLF
Contact
PetLife Pharmaceuticals, Inc.
433 N. Camden Dr.
Beverly Hills, CA 90210
T: (310) 279-5152
www.PetLifePharma.com
Sebastian Serrell-Watts
Co-founder, Executive Vice President
E: info@petlifepharma.com
Investor Relations:
MZ Group
Greg Falesnik, Senior Vice President
T: (949) 385-6449
E: greg.falesnik@mzgroup.us